Literature DB >> 25451988

Aspirin for primary prevention: what's a clinician to do?

Mitchell A Psotka1, Kirsten E Fleischmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25451988      PMCID： PMC4314501          DOI： 10.1007/s11606-014-3108-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  9 in total

1.  Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.

Authors:  Michael Pignone; Mark J Alberts; John A Colwell; Mary Cushman; Silvio E Inzucchi; Debabrata Mukherjee; Robert S Rosenson; Craig D Williams; Peter W Wilson; M Sue Kirkman
Journal:  Circulation       Date:  2010-05-27       Impact factor: 29.690

2.  The new cholesterol and blood pressure guidelines: perspective on the path forward.

Authors:  Harlan M Krumholz
Journal:  JAMA       Date:  2014-04-09       Impact factor: 56.272

3.  Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Per Olav Vandvik; A Michael Lincoff; Joel M Gore; David D Gutterman; Frank A Sonnenberg; Pablo Alonso-Coello; Elie A Akl; Maarten G Lansberg; Gordon H Guyatt; Frederick A Spencer
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2009-03-17       Impact factor: 25.391

5.  Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?

Authors:  Kevin Fiscella; Paul C Winters; Michael Mendoza; Gary J Noronha; Carlos M Swanger; John D Bisognano; Robert J Fortuna
Journal:  J Gen Intern Med       Date:  2015-02       Impact factor: 5.128

Review 6.  Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials.

Authors:  Sreenivasa Rao Kondapally Seshasai; Shanelle Wijesuriya; Rupa Sivakumaran; Sarah Nethercott; Sebhat Erqou; Naveed Sattar; Kausik K Ray
Journal:  Arch Intern Med       Date:  2012-01-09

Review 7.  Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials.

Authors:  Paul Sutcliffe; Martin Connock; Tara Gurung; Karoline Freeman; Samantha Johnson; Kandala Ngianga-Bakwin; Amy Grove; Binu Gurung; Sarah Morrow; Saverio Stranges; Aileen Clarke
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

8.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

9.  Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility.

Authors:  Marianna Fontana; Perviz Asaria; Michela Moraldo; Judith Finegold; Khalil Hassanally; Charlotte H Manisty; Darrel P Francis
Journal:  Circulation       Date:  2014-04-17       Impact factor: 29.690
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.